What is Science?
Science Corporation is recognized in the industry as a clinical-stage medical technology firm dedicated to pioneering neural interface and neuro-engineering solutions. The company's core focus lies in developing advanced biohybrid neural interfaces and devices designed to restore vision, cognition, and mobility for individuals with severe neurological conditions. By integrating extensive research, clinical trials, and a vertically integrated infrastructure, Science aims to bridge the gap between laboratory discoveries and practical patient applications, positioning itself at the forefront of neuro-restorative medicine.
How much funding has Science raised?
Science has raised a total of $230M across 1 funding round:
Series C
$230M
Series C (2026): $230M with participation from In-Q-Tel, Quiet Capital, Lightspeed Venture Partners, Y Combinator, and Khosla Ventures
Key Investors in Science
In-Q-Tel
In-Q-Tel is a venture capital firm that serves as the U.S. national security community's investment arm, focusing on early-stage commercial technology companies in sectors such as biotech and AI.
Quiet Capital
Quiet Capital is a founder-led venture capital firm that supports technology entrepreneurs with patient capital and operational expertise across various markets, including health.
Lightspeed Venture Partners
Lightspeed Venture Partners is a global venture capital firm that invests in early and growth-stage technology companies across enterprise software, consumer, and fintech sectors.
What's next for Science?
With the recent major strategic investment and substantial overall capital, Science is poised for significant growth and scaling. The company's trajectory suggests a move towards later-stage development and market entry, leveraging its advanced platform to address critical unmet needs in neurological health. Future endeavors will likely involve expanding clinical validation, navigating regulatory pathways, and potentially forging strategic partnerships to broaden the reach of its life-changing technologies. The substantial backing indicates strong investor confidence in Science's vision and its potential to revolutionize neuro-restorative treatments.
See full Science company page
